UK company is in the transition stage from discovery to development of treatments for cancer
Mission Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, has appointed Anker Lundemose as Chief Executive.
Lundemose brings extensive experience to Mission at a pivotal stage in its evolution, as it transitions from discovery to development.
In a biopharma career spanning over two and a half decades, Lundemose was most recently CEO of Norwegian vaccine company Bionor Pharma, and previously co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, subsequently reversed into OSI.
Last June, Mission received £150,000 from the UK's Biomedical Catalyst to develop desumoylating enzyme inhibitors for the treatment of drug-resistant cancers.